The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias

Emmanouil Athanasakis, Elisabetta Melloni, Gian Matteo Rigolin, Chiara Agnoletto, Rebecca Voltan, Diego Vozzi, Elisa Piscianz, Ludovica Segat, Simeone Dal Monego, Antonio Cuneo, Paola Secchiero, Giorgio Zauli

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

By using next generation sequencing, we have analyzed 108 B chronic lymphocytic leukemia (B-CLL) patients. Among genes involved in the TP53 pathway, we found frequent mutations in ATM (n=18), TP53 (n=10) and NOTCH1 (n=10) genes, rare mutations of NOTCH2 (n=2) and CDKN1A/p21 (n=1) and no mutations in BAX, MDM2, TNFRSF10A and TNFRSF10B genes. The in vitro treatment of primary B-CLL cells with the activator of p53 Nutlin-3 induced the transcription of p53 target genes, without significant differences between the B-CLL without mutations and those harboring either ATM or NOTCH1 mutations. On the other hand, the subgroup of TP53mutated B-CLL exhibited a significantly lower induction of the p53 target genes in response to Nutlin-3 as compared to the other B-CLL samples. However, among the TP53mutated B-CLL, those showing mutations in the high hot spot region of the DNA binding domain [273-280 aa] maintained a significantly higher p53-dependent transcriptional activity as compared to the other TP53mutated B-CLL samples. Since the ability to elicit a p53-dependent transcriptional activity in vitro has a positive prognostic significance, our data suggest that ATMmutated, NOTCH1mutated and surprisingly, also a subset of TP53mutated B-CLL patients might benefit from therapeutic combinations including small molecule activator of the p53 pathway.

Original languageEnglish
Pages (from-to)12635-12645
Number of pages11
JournalOncotarget
Volume5
Issue number24
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Mutation
p53 Genes
Genes
DNA
Therapeutics

Keywords

  • ATM
  • B-CLL
  • NOTCH1
  • Nutlin-3
  • P53

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Athanasakis, E., Melloni, E., Rigolin, G. M., Agnoletto, C., Voltan, R., Vozzi, D., ... Zauli, G. (2014). The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias. Oncotarget, 5(24), 12635-12645.

The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias. / Athanasakis, Emmanouil; Melloni, Elisabetta; Rigolin, Gian Matteo; Agnoletto, Chiara; Voltan, Rebecca; Vozzi, Diego; Piscianz, Elisa; Segat, Ludovica; Dal Monego, Simeone; Cuneo, Antonio; Secchiero, Paola; Zauli, Giorgio.

In: Oncotarget, Vol. 5, No. 24, 2014, p. 12635-12645.

Research output: Contribution to journalArticle

Athanasakis, E, Melloni, E, Rigolin, GM, Agnoletto, C, Voltan, R, Vozzi, D, Piscianz, E, Segat, L, Dal Monego, S, Cuneo, A, Secchiero, P & Zauli, G 2014, 'The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias', Oncotarget, vol. 5, no. 24, pp. 12635-12645.
Athanasakis E, Melloni E, Rigolin GM, Agnoletto C, Voltan R, Vozzi D et al. The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias. Oncotarget. 2014;5(24):12635-12645.
Athanasakis, Emmanouil ; Melloni, Elisabetta ; Rigolin, Gian Matteo ; Agnoletto, Chiara ; Voltan, Rebecca ; Vozzi, Diego ; Piscianz, Elisa ; Segat, Ludovica ; Dal Monego, Simeone ; Cuneo, Antonio ; Secchiero, Paola ; Zauli, Giorgio. / The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias. In: Oncotarget. 2014 ; Vol. 5, No. 24. pp. 12635-12645.
@article{5260cdb5538449e393f58a74d68618ea,
title = "The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias",
abstract = "By using next generation sequencing, we have analyzed 108 B chronic lymphocytic leukemia (B-CLL) patients. Among genes involved in the TP53 pathway, we found frequent mutations in ATM (n=18), TP53 (n=10) and NOTCH1 (n=10) genes, rare mutations of NOTCH2 (n=2) and CDKN1A/p21 (n=1) and no mutations in BAX, MDM2, TNFRSF10A and TNFRSF10B genes. The in vitro treatment of primary B-CLL cells with the activator of p53 Nutlin-3 induced the transcription of p53 target genes, without significant differences between the B-CLL without mutations and those harboring either ATM or NOTCH1 mutations. On the other hand, the subgroup of TP53mutated B-CLL exhibited a significantly lower induction of the p53 target genes in response to Nutlin-3 as compared to the other B-CLL samples. However, among the TP53mutated B-CLL, those showing mutations in the high hot spot region of the DNA binding domain [273-280 aa] maintained a significantly higher p53-dependent transcriptional activity as compared to the other TP53mutated B-CLL samples. Since the ability to elicit a p53-dependent transcriptional activity in vitro has a positive prognostic significance, our data suggest that ATMmutated, NOTCH1mutated and surprisingly, also a subset of TP53mutated B-CLL patients might benefit from therapeutic combinations including small molecule activator of the p53 pathway.",
keywords = "ATM, B-CLL, NOTCH1, Nutlin-3, P53",
author = "Emmanouil Athanasakis and Elisabetta Melloni and Rigolin, {Gian Matteo} and Chiara Agnoletto and Rebecca Voltan and Diego Vozzi and Elisa Piscianz and Ludovica Segat and {Dal Monego}, Simeone and Antonio Cuneo and Paola Secchiero and Giorgio Zauli",
year = "2014",
language = "English",
volume = "5",
pages = "12635--12645",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "24",

}

TY - JOUR

T1 - The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias

AU - Athanasakis, Emmanouil

AU - Melloni, Elisabetta

AU - Rigolin, Gian Matteo

AU - Agnoletto, Chiara

AU - Voltan, Rebecca

AU - Vozzi, Diego

AU - Piscianz, Elisa

AU - Segat, Ludovica

AU - Dal Monego, Simeone

AU - Cuneo, Antonio

AU - Secchiero, Paola

AU - Zauli, Giorgio

PY - 2014

Y1 - 2014

N2 - By using next generation sequencing, we have analyzed 108 B chronic lymphocytic leukemia (B-CLL) patients. Among genes involved in the TP53 pathway, we found frequent mutations in ATM (n=18), TP53 (n=10) and NOTCH1 (n=10) genes, rare mutations of NOTCH2 (n=2) and CDKN1A/p21 (n=1) and no mutations in BAX, MDM2, TNFRSF10A and TNFRSF10B genes. The in vitro treatment of primary B-CLL cells with the activator of p53 Nutlin-3 induced the transcription of p53 target genes, without significant differences between the B-CLL without mutations and those harboring either ATM or NOTCH1 mutations. On the other hand, the subgroup of TP53mutated B-CLL exhibited a significantly lower induction of the p53 target genes in response to Nutlin-3 as compared to the other B-CLL samples. However, among the TP53mutated B-CLL, those showing mutations in the high hot spot region of the DNA binding domain [273-280 aa] maintained a significantly higher p53-dependent transcriptional activity as compared to the other TP53mutated B-CLL samples. Since the ability to elicit a p53-dependent transcriptional activity in vitro has a positive prognostic significance, our data suggest that ATMmutated, NOTCH1mutated and surprisingly, also a subset of TP53mutated B-CLL patients might benefit from therapeutic combinations including small molecule activator of the p53 pathway.

AB - By using next generation sequencing, we have analyzed 108 B chronic lymphocytic leukemia (B-CLL) patients. Among genes involved in the TP53 pathway, we found frequent mutations in ATM (n=18), TP53 (n=10) and NOTCH1 (n=10) genes, rare mutations of NOTCH2 (n=2) and CDKN1A/p21 (n=1) and no mutations in BAX, MDM2, TNFRSF10A and TNFRSF10B genes. The in vitro treatment of primary B-CLL cells with the activator of p53 Nutlin-3 induced the transcription of p53 target genes, without significant differences between the B-CLL without mutations and those harboring either ATM or NOTCH1 mutations. On the other hand, the subgroup of TP53mutated B-CLL exhibited a significantly lower induction of the p53 target genes in response to Nutlin-3 as compared to the other B-CLL samples. However, among the TP53mutated B-CLL, those showing mutations in the high hot spot region of the DNA binding domain [273-280 aa] maintained a significantly higher p53-dependent transcriptional activity as compared to the other TP53mutated B-CLL samples. Since the ability to elicit a p53-dependent transcriptional activity in vitro has a positive prognostic significance, our data suggest that ATMmutated, NOTCH1mutated and surprisingly, also a subset of TP53mutated B-CLL patients might benefit from therapeutic combinations including small molecule activator of the p53 pathway.

KW - ATM

KW - B-CLL

KW - NOTCH1

KW - Nutlin-3

KW - P53

UR - http://www.scopus.com/inward/record.url?scp=84921366247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921366247&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 12635

EP - 12645

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 24

ER -